SOURCE: Cytovance Biologics

Cytovance Biologics

November 03, 2015 05:00 ET

BiondVax Pharmaceuticals Ltd. Selects Cytovance® Biologics Inc. for the Manufacturing of M-001 the Universal Flu Vaccine for Phase III Clinical Trials

OKLAHOMA CITY, OK--(Marketwired - November 03, 2015) - Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE: BVXV) (NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.

Under the terms of the Agreement, Cytovance® Biologics will scale up and optimize the manufacturing process of M-001. The transfer of technology will start immediately, with the Phase III batches manufactured as soon as Q4 2016. The M-001 batch will be used by BiondVax in a phase III trial planned for 2017-2018.

Ron Babecoff, CEO of BiondVax commented: "This strategic partnership with Cytovance® Biologics, a US leader in contract manufacturing with a significant track record in production of clinical materials, is very important to BiondVax. I am pleased to see our clinical program is now taking a significant step forward. This manufacturing agreement marks a major milestone towards our progression to the advanced phases of our clinical development program."

Darren Head, CEO and President of Cytovance added: "Cytovance's state-of-the-art facilities and staff are prepared to deliver the highest quality of manufacturing services for BiondVax."

About BiondVax Pharmaceuticals Ltd

BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.

BiondVax's technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

About Cytovance Biologics Inc.

Cytovance® Biologics is a contract development manufacturing company specializing in the cGMP production of therapeutic proteins and antibodies from mammalian cell culture, microbial fermentation, transgenic processes, and small scale "flex suite" programs. In addition, Cytovance offers process development services, cell line development, purification development, stability testing, and regulatory support services -- all from its Oklahoma City state-of-the-art facilities.

Contact Information

  • Media Contact:
    Cheryl Soerensen
    Marketing & Communications Manager
    Email contact